Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

Deltanoid Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Plaque-type Psoriasis

Treatments: Drug: Placebo; Drug: COL-121; Drug: 50 µg/g Calcipotriene Ointment

Study type: Interventional

Funder types: Industry

Identifiers

NCT00625326

COL-121-PSOR-201

Details and patient eligibility

About

Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was observed. These effects were reversible with discontinuation of therapy. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.

Full description

Psoriasis affects more than 7 million Americans. Plaque-type psoriasis (the most common type of psoriasis) is an inflammatory skin condition with reactive abnormal epidermal differentiation and hyperproliferation. It is characterized by raised, thickened, plaques of erythematous skin covered by a silvery-white scale. Plaque-type psoriasis is most commonly found on the knees, elbows, and scalp but can appear anywhere on the body. While patients with psoriasis may complain of itchiness and discomfort, the psychological effects of the disease are the most debilitating. In a 1998 survey conducted by the National Psoriasis Foundation, it was found that 79% of the psoriasis patients surveyed reported that the disease had a negative impact on their lives and 40% felt frustrated with the ineffectiveness of their current therapies.

Although the exact cause of this skin disease is unknown, it is clear that immune-based inflammatory mechanisms initiate an accelerated growth of skin cells. This accelerated growth results in an agglomeration of skin cells on the surface of the epidermis that the body cannot shed. This agglomeration creates the thickened patches of scaly skin characteristic of the disease.

Clinical use of systemic vitamin D to treat psoriasis has been limited because of the induction of hypercalcemia. In contrast, low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Topical vitamin D analogs have the ability to inhibit the proliferation and promote the differentiation of keratinocytes in psoriatic skin. In addition, vitamin D analogs may also act by inhibiting cytokine production by keratinocytes or lymphocytes. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. In patients with extensive psoriasis, calcipotriol ointment was shown to be effective. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was recorded in 3 patients. These effects were reversible with discontinuation of therapy. In a review of the effects on calcium homeostasis, it was noted that calcipotriol (50 µg/g) had no effects on serum or urine calcium when administered at doses of 40-50 g/week and two reports of hypercalcemia at doses of 70-100 g/week. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Subsequently, calcipotriol and tacalcitol, another vitamin D analog, have become first-line therapies in the management of "mild to moderate" psoriasis in several countries in Western Europe, Japan and the USA.

Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.

Enrollment: 321 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Psoriasis must affect at least 2% and not more than 10% of the subject's body surface area, excluding the face and scalp
• Subject must have 2 to 4 target plaques on the area to be treated, excluding the face and scalp.
• Subjects who are women of childbearing potential must have a negative pregnancy test and be non-lactating.
• Subjects who are women of childbearing potential must utilize one of the following methods of birth control throughout the study: IUD, diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 4 months prior to Visit 1 and has not changed the brand within this period). Subjects may also participate if they are surgically sterilized, in a monogamous relationship with a sterile partner, or abstain from sexual intercourse during the course of the study.
• Subjects must be in good general health and free of any disease state or physical condition that, in the investigator's opinion, may interfere with study evaluations or exposes the subject to unacceptable risk by study participation.
• Subject must be willing and able to apply the study medication as directed, comply with the study instructions, and commit to all the follow-up visits for the duration of the study.
• Subjects must sign an informed consent form.

Exclusion criteria

• Subjects who have guttate, pustular, erythrodermic or other non-plaque types of psoriasis.
• Subjects who have spontaneously improving or rapidly deteriorating plaque psoriasis.
• Subjects who have used systemic immunomodulatory therapy known to affect psoriasis and to typically decrease immune cell populations (e.g., alefacept) within the previous 40 weeks.
• Subjects who have used any systemic immunomodulatory therapy known to affect psoriasis and to NOT typically decrease immune cell populations (e.g., etanercept) within the previous 16 weeks.
• Subjects who have used any photo-therapy (including laser), photo-chemotherapy or systemic psoriasis therapy (e.g., systemic corticosteroids, methotrexate, retinoids, cyclosporine) within the previous 12 weeks.
• Subjects who have had prolonged exposure to natural or artificial sources of ultraviolet radiation within the previous 3 weeks or are intending to have such exposure during the study, thought by the investigator likely to modify the subject's plaque psoriasis.
• Subjects who have used topical anti-psoriatic therapy (including topical retinoids) on the areas to be evaluated within the previous 2 weeks.
• Subjects who have used emollients/moisturizers on the areas to be evaluated within the previous 1 day.
• Subjects who have untreated bacterial, tubercular, fungal or viral lesions of the skin on the areas to be evaluated.
• Subjects who have known sensitivity to a component of the study medication or to topical or systemic vitamin D.
• Subjects who have any significant condition such as diseases of the hepatic, renal, endocrine, musculoskeletal, or nervous system, or any gross physical impairment.
• Subjects who have taken a vitamin D supplement that exceeds 400 IU per day in the previous 30 days.
• Subjects who have taken a calcium supplement that exceeds 1200 mg per day in the previous 30 days.
• Subjects who are using lithium or Plaquenil.
• Subjects who are using beta-blocking medication or thiazide diuretics whose dose has not been stable for at least 12 weeks.
• Subjects who have a history of hypercalcemia or evidence of vitamin D toxicity.
• Subjects who are currently being treated for malignancy or have been diagnosed with melanoma within the past 5 years.
• Subjects who have received any investigational treatment(s) within the previous 30 days.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

321 participants in 5 patient groups, including a placebo group

75 µg/g COL-121 Ointment

Experimental group

Description:

75 µg/g COL-121 Ointment

Treatment:

Drug: COL-121

Drug: COL-121

Drug: COL-121

150 µg/g COL-121 Ointment

Experimental group

Description:

150 µg/g COL-121 Ointment

Treatment:

Drug: COL-121

Drug: COL-121

Drug: COL-121

300 µg/g COL-121 Ointment

Experimental group

Description:

300 µg/g COL-121 Ointment

Treatment:

Drug: COL-121

Drug: COL-121

Drug: COL-121

50 µg/g Calcipotriene Ointment

Active Comparator group

Description:

50 µg/g Calcipotriene Ointment (active control)

Treatment:

Drug: 50 µg/g Calcipotriene Ointment

Placebo Ointment

Placebo Comparator group

Description:

Placebo Ointment

Treatment:

Drug: Placebo